CGH Podcast January 2012: Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model
The Study of Biologic and Immunomodulator-Naïve Patients With Crohn's Disease (SONIC) showed that combination therapy with infliximab and azathioprine (IFX/AZA) is more effective than treatment with IFX alone. While enrollment was limited, numbers and types of adverse events were roughly equivalent among groups. A study in the January 2012 issue of CGH sought to define the frequency at which a rare adverse event would have to occur for the risks of combination therapy to outweigh the benefits of treatment. Dr. Kuemmerle speaks with author Dr. Corey Siegel of the Dartmouth-Hitchcock Inflammatory Bowel Disease Center; Plus, summaries of the top stories from this month's issue of GI and Hepatology News.
Siegel CA, Finlayson SRG, Sands BE. Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model. Clinical Gastroenterology & Hepatology 2012; Jan; 10(1): 46-51
Duration: 19.31
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ
Download: /attachments/cgh_podcast_january_2012.mp3
